<i>CAT</i> rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia
Marilisa Galasso(University of Verona), Maria Teresa Scupoli(University of Verona), Isacco Ferrarini(University of Verona), Mauro Krampera(University of Verona), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ester Lovato(University of Verona), Ornella Lovato(University of Verona), Carlo Visco(University of Verona), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Massimo Donadelli(University of Verona), Francesca Maria Quaglia(University of Verona), Chiara Cosentino(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Valentina Mozzo(Istituto Oncologico Veneto), Maria Elena Carazzolo(University of Verona), Maria Romanelli(University of Verona), Simona Gambino(University of Verona), Vittoria Salaorni(University of Verona), Omar Perbellini(University of Verona)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682